540 related articles for article (PubMed ID: 29660214)
1. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
[TBL] [Abstract][Full Text] [Related]
3. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
[TBL] [Abstract][Full Text] [Related]
4. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
5. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.
Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Danel C; Delaugerre C; Zoulim F; Lacombe K;
Liver Int; 2019 Feb; 39(2):280-289. PubMed ID: 30257068
[TBL] [Abstract][Full Text] [Related]
6. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
7. Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
Yang R; Gui X; Ke H; Xiong Y; Gao S
J Viral Hepat; 2020 Feb; 27(2):127-134. PubMed ID: 31571343
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus.
Pivert A; Servant-Delmas A; Lunel-Fabiani F; Le Guillou-Guillemette H; Laperche S; Ducancelle A
J Med Virol; 2015 Mar; 87(3):529-35. PubMed ID: 25170961
[TBL] [Abstract][Full Text] [Related]
9. The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response.
Peng Y; Li Y; Hou J; Sun J; Su M; Li Y; Xiang K; Yan L; Zhuang H; Li T
Infect Genet Evol; 2017 Apr; 49():116-121. PubMed ID: 28088502
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
[TBL] [Abstract][Full Text] [Related]
11. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients.
Yan CH; Zhao CY; Ding H; Peng YQ; Jin PY; Yan L; Zhuang H; Li T
Antiviral Res; 2012 Nov; 96(2):108-14. PubMed ID: 22960603
[TBL] [Abstract][Full Text] [Related]
13. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
14. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
15. Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by Simpleprobe.
Tu WH; Lv Y; Zhang YM; Hou W; Wang JY; Zhang YJ; Liu HY; Zhu HX; Qin YL; Mao RC; Zhang JM
World J Gastroenterol; 2015 Jun; 21(21):6639-48. PubMed ID: 26074702
[TBL] [Abstract][Full Text] [Related]
16. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients.
Hu HH; Liu J; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; Quan Y; Xia NS; Chen CJ; Chen PJ; Yang HI
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):172-181.e1. PubMed ID: 29753083
[TBL] [Abstract][Full Text] [Related]
17. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients.
Huang YH; Wu JC; Chang TT; Sheen IJ; Huo TI; Lee PC; Su CW; Lee SD
J Viral Hepat; 2006 May; 13(5):336-42. PubMed ID: 16637865
[TBL] [Abstract][Full Text] [Related]
18. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
[TBL] [Abstract][Full Text] [Related]
19. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
He Y; Lin W; Li H; Gu F; Zhong H; Lan Y; Li Y; Guo P; Hu F; Cai W; Tang X; Li L
Chin Med J (Engl); 2023 Nov; 136(22):2686-2693. PubMed ID: 37881959
[TBL] [Abstract][Full Text] [Related]
20. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P
J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
